SciBase Updates Trading Dates for Subscription Rights and Paid Shares on Nasdaq

SciBase Updates Trading Dates for Subscription Rights and Paid Shares

Stockholm, Sweden – On September 15, 2026, SciBase Holding AB, a prominent medical technology firm specializing in dermatology, officially announced an update regarding its upcoming trading activities on the Nasdaq First North Growth Market. The company has modified the schedule for the initial trading day of subscription rights and paid subscribed shares, known as BTA (Bolagets Teckningsaktier), amidst its current rights issue of shares.

Initially, the first day designated for trading these securities was set for September 15, 2026. However, the latest announcement from SciBase indicates that this date has been rescheduled to September 16, 2026. This change is part of the company's strategic planning around its rights offering, intended to enhance shareholder engagement and market activity.

Rights Issue Overview

The subscription rights and BTA trading periods have been clearly outlined in the updated timetable. The subscription period will remain unchanged, extending from September 15 to September 29, 2026. This allows current shareholders to exercise their rights and participate in the capital increase that SciBase aims to achieve through this rights offering.

The subsequent period for trading subscription rights will occur from September 16 to September 24, 2026, while the trading period for paid subscribed shares (BTA) will run from September 16 to October 16, 2026. The company anticipates announcing the outcome of the rights issue on October 1, 2026, providing insights into shareholder participation and the success of the fundraising initiative.

The Significance of the Rights Issue

The rights issue is a critical step for SciBase as it seeks to bolster its capital structure and support future growth initiatives. With the development of innovative technologies for skin health management, particularly with the integration of AI within its flagship product, Nevisense, an enhanced financial footing will empower the company to further refine its offerings and expand its market presence.

SciBase's commitment to early detection in dermatology positions it at the forefront of medical technology advancements. The company is driven by its vision to minimize patient suffering and enhance clinical outcomes, demonstrating its dedication to a proactive approach in skin health management. The Company’s long-standing research ties with the prestigious Karolinska Institute bolster its credibility within the industry, providing a strong foundation for its R&D endeavors.

Consequently, this rights issue and the associated trading modifications are expected to foster increased investor interest as SciBase continues its trajectory of innovation and market leadership. Shareholders and potential investors alike are encouraged to remain informed and consider the implications of this rights issue as the various trading periods unfold. Any additional inquiries regarding the rights issue can be directed to Michael Colérus, the Chief Financial Officer, who has made himself available for contact at +46 70 341 34 72.

For ongoing updates and crucial announcements, stakeholders are advised to monitor the company’s official channels, including its investor relations webpage.

Important Note

It is crucial to mention that this release is aimed solely at potential investors familiar with the implications of such financial moves. The invitation to subscribe to securities or engage with the rights issue is strictly limited to certain jurisdictions, with compliance to specific legal stipulations being paramount. Interested parties outside Sweden should familiarize themselves with applicable laws and regulations relevant to share subscriptions.

For more detailed information on the rights issue and upcoming trading activities, please visit the official SciBase website or consult the relevant investment documentation.

In conclusion, the adjustment in the first trading day reflects SciBase’s commitment to ensuring a smooth and compliant capital-raising effort while simultaneously pushing the boundaries of innovation in dermatology.